TY - JOUR
T1 - Novel cancer immunotherapy agents with survival benefit
T2 - Recent successes and next steps
AU - Sharma, Padmanee
AU - Wagner, Klaus
AU - Wolchok, Jedd D.
AU - Allison, James P.
N1 - Funding Information:
The authors’ research work was supported by the Howard Hughes Medical Institute (for J.P.A.), the Ludwig Center for Cancer Immunotherapy (for P.S., J.D.W. and J.P.A.), a Prostate Cancer Foundation Challenge Award in Immunology (to P.S. and J.P.A.). P.S. also acknowledges support from an M. D. Anderson Cancer Center Physician Scientist Award, a Doris Duke Charitable Foundation Clinical Scientist Development Award, a Clinical Investigator Award from the Cancer Research Institute, a Melanoma Research Alliance Young Investigator Award, an American Cancer Society Mentored Research Scholar Grant and a US Department of Defense Prostate Cancer Idea Development Award.
PY - 2011/11
Y1 - 2011/11
N2 - The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provideclinical benefit are not completely understood. However, knowledge of these mechanisms will be crucial for probing human immune responses and tumour biology in order to understand what distinguishes responders from non-responders. The following next steps are necessary: first, the development of immune-monitoring strategies for the identification of relevant biomarkers; second, the establishment of guidelines for the assessment of clinical end points; and third, the evaluation of combination therapy strategies to improve clinical benefit.
AB - The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provideclinical benefit are not completely understood. However, knowledge of these mechanisms will be crucial for probing human immune responses and tumour biology in order to understand what distinguishes responders from non-responders. The following next steps are necessary: first, the development of immune-monitoring strategies for the identification of relevant biomarkers; second, the establishment of guidelines for the assessment of clinical end points; and third, the evaluation of combination therapy strategies to improve clinical benefit.
UR - http://www.scopus.com/inward/record.url?scp=80054875641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054875641&partnerID=8YFLogxK
U2 - 10.1038/nrc3153
DO - 10.1038/nrc3153
M3 - Review article
C2 - 22020206
AN - SCOPUS:80054875641
SN - 1474-175X
VL - 11
SP - 805
EP - 812
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 11
ER -